Treatment of primary breast cancer with immunotherapy. Comparison with adjuvant chemotherapy and radiation therapy.
For the first time, data on 78 breast cancer patients treated by modified radical mastectomy and adjuvant immunotherapy have been reported. Thirty-nine lymph node negative patients with uninvolved lymph nodes had a projected 5 year survival rate of 94 percent and 39 patients with involved nodes had a projected 5 year survival rate of 77 percent and a disease-free survival rate of 70 percent. Results have been presented according to UICC staging. The 100 percent survival rate of stage I patients has been compared with rates obtained by treatment of breast cancer with radiation therapy as the principal modality. The preliminary data are promising enough to warrant randomized, prospective trials with the other adjuvant modalities.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008207:Lymphatic Metastasis; D008408:Mastectomy
D000970:Antineoplastic Agents